Aberrant expression of polo‑like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long‑term survival

Jiang,Wenxia; Zhao,Yan; Zhang,Suxia; Zeng,Yu; Ma,Jun

doi:10.3892/ol.2022.13547

Aberrant expression of polo‑like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long‑term survival

Authors:
- Wenxia Jiang
- Yan Zhao
- Suxia Zhang
- Yu Zeng
- Jun Ma
View Affiliations

Affiliations: School of Clinical Medicine, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China, Experimental Centre of Medicine and Life Science, Tongji University, Shanghai 200331, P.R. China, Department of Pathology, Tongji Hospital of Tongji University, Shanghai 200065, P.R. China, Department of Nephrology, Jing'an District Center Hospital of Shanghai, Fudan University, Shanghai 200040, P.R. China
Published online on: October 14, 2022 https://doi.org/10.3892/ol.2022.13547
Article Number: 427
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polo‑like kinase 4 (PLK4) promotes tumorigenesis and is associated with the prognosis of several solid tumors, while its clinical role in patients with renal cell carcinoma (RCC) remains unidentified. The present study aimed to analyze the association of PLK4 with clinicopathological characteristics and long‑term prognosis in patients with RCC. The present study detected PLK4 protein and mRNA expression using immunohistochemical and reverse transcription‑quantitative PCR assays in 120 patients with RCC. Disease‑free survival (DFS) and overall survival (OS) time were calculated based on a median follow‑up duration of 6.9 years (range, 1.2‑9.9 years). PLK4 protein expression was elevated in tumor tissues compared with adjacent tissues (P<0.001). Upregulation of PLK4 protein was associated with increased T stage (P=0.023), N stage (P=0.014) and TNM stage (P=0.007). Additionally, elevated tumor PLK4 protein expression exhibited an associating trend (without statistical significance) with reduced DFS rate (P=0.066) and was associated with decreased OS rate (P=0.036). However, univariate Cox's regression analysis indicated that high PLK4 protein expression (compared with low PLK4 protein expression) was associated with reduced OS rate (P=0.040) but not with PFS rate (P=0.070). Following adjustment by multivariate Cox's regression analysis, PLK4 protein expression was associated with neither DFS nor OS rate (both P>0.050). Additionally, PLK4 mRNA expression was further detected in some patients (for which fresh specimens frozen in liquid nitrogen were available) to validate the aforementioned observations, and the expression was elevated in tumor tissues compared with adjacent tissues. Furthermore, increased PLK4 mRNA expression was associated with tumor size ≥7 cm, high TNM stage and reduced DFS rate (all P<0.050). PLK4 possesses a certain clinical utility in monitoring the clinical stage of patients with RCC, while its prognostic value requires further validation.

View Figures

View References

1	Gray RE and Harris GT: Renal cell carcinoma: Diagnosis and management. Am Fam Physician. 99:179–184. 2019.PubMed/NCBI
2	Padala SA and Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A: Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87. 2020. View Article : Google Scholar : PubMed/NCBI
3	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
4	Chen Q, Zheng RS, Zhang SK, Zhang SW, Liu SZ, Sun XB, Wei WW and He J: Cancer incidence and mortality of kidney and unspecified urinary organs in China, 2015. Zhonghua Zhong Liu Za Zhi. 42:1001–1006. 2020.(In Chinese). PubMed/NCBI
5	Tang T, Du X, Zhang X, Niu W, Li C and Tan J: Computational identification and analysis of early diagnostic biomarkers for kidney cancer. J Hum Genet. 64:1015–1022. 2019. View Article : Google Scholar : PubMed/NCBI
6	Maestroni U, Gasparro D, Ziglioli F, Guarino G and Campobasso D: Metastatic clear cell renal cell carcinoma: The great pretender and the great dilemma. World J Oncol. 12:178–182. 2021. View Article : Google Scholar : PubMed/NCBI
7	Guo Q, Zhang C, Guo X, Tao F, Xu Y, Feng G, Han X, Ren Z, Zhang H, Zhang P, et al: Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: A population-based study. Cancer Manag Res. 10:2935–2944. 2018. View Article : Google Scholar : PubMed/NCBI
8	Lai GS, Li JR, Wang SS, Chen CS, Yang CK, Hung SC, Cheng CL, Ou YC and Chiu KY: Tumor size significantly affects prognosis in pathological T3a renal cell carcinoma. Anticancer Res. 42:2185–2191. 2022. View Article : Google Scholar : PubMed/NCBI
9	Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, et al: Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: A retrospective cohort study. Acta Oncol. 61:22–29. 2022. View Article : Google Scholar : PubMed/NCBI
10	Zhao Y and Wang X: PLK4: A promising target for cancer therapy. J Cancer Res Clin Oncol. 145:2413–2422. 2019. View Article : Google Scholar : PubMed/NCBI
11	Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, et al: Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem. 285:2807–2822. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hoffmann I: Role of polo-like kinases Plk1 and Plk4 in the initiation of centriole duplication-impact on cancer. Cells. 11:7862022. View Article : Google Scholar : PubMed/NCBI
13	Liao Z, Zhang H, Fan P, Huang Q, Dong K, Qi Y, Song J, Chen L, Liang H, Chen X, et al: High PLK4 expression promotes tumor progression and induces epithelialmesenchymal transition by regulating the Wnt/betacatenin signaling pathway in colorectal cancer. Int J Oncol. 54:479–490. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zhou Q, Fan G and Dong Y: Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer. J Clin Lab Anal. 34:e231522020. View Article : Google Scholar : PubMed/NCBI
15	Singh CK, Denu RA, Nihal M, Shabbir M, Garvey DR, Huang W, Iczkowski KA and Ahmad N: PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence. Prostate. 82:957–969. 2022. View Article : Google Scholar : PubMed/NCBI
16	Holland AJ and Cleveland DW: Polo-like kinase 4 inhibition: A strategy for cancer therapy? Cancer Cell. 26:151–153. 2014. View Article : Google Scholar : PubMed/NCBI
17	Zhang X, Wei C, Liang H and Han L: Polo-like kinase 4′s critical role in cancer development and strategies for Plk4-targeted therapy. Front Oncol. 11:5875542021. View Article : Google Scholar : PubMed/NCBI
18	Yang Z, Sun H, Ma W, Wu K, Peng G, Ou T and Wu S: Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer. FEBS Open Bio. 11:2631–2646. 2021. View Article : Google Scholar : PubMed/NCBI
19	Garvey DR, Chhabra G, Ndiaye MA and Ahmad N: Role of polo-like kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for cancer management. Mol Cancer Ther. 20:632–640. 2021. View Article : Google Scholar : PubMed/NCBI
20	Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019. View Article : Google Scholar : PubMed/NCBI
21	Zhang G, Zhang Z and Liu Z: Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol. 34:1887–1894. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hu Z, Gu X, Zhong R and Zhong H: Tumor-infiltrating CD45RO(+) memory cells correlate with favorable prognosis in patients with lung adenocarcinoma. J Thorac Dis. 10:2089–2099. 2018. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
25	Kazazian K, Go C, Wu H, Brashavitskaya O, Xu R, Dennis JW, Gingras AC and Swallow CJ: Plk4 promotes cancer invasion and metastasis through Arp2/3 complex regulation of the actin cytoskeleton. Cancer Res. 77:434–447. 2017. View Article : Google Scholar : PubMed/NCBI
26	Mittal K, Kaur J, Sharma S, Sharma N, Wei G, Choudhary I, Imhansi-Jacob P, Maganti N, Pawar S, Rida P, et al: Hypoxia drives centrosome amplification in cancer cells via HIF1alpha-dependent Induction of Polo-Like Kinase 4. Mol Cancer Res. 20:596–606. 2022. View Article : Google Scholar : PubMed/NCBI
27	Kim DH, Ahn JS, Han HJ, Kim HM, Hwang J, Lee KH, Cha-Molstad H, Ryoo IJ, Jang JH, Ko SK, et al: Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stability. Cell Death Dis. 10:5702019. View Article : Google Scholar : PubMed/NCBI
28	Holland AJ, Lan W, Niessen S, Hoover H and Cleveland DW: Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. J Cell Biol. 188:191–198. 2010. View Article : Google Scholar : PubMed/NCBI
29	Kurinna S, Stratton SA, Coban Z, Schumacher JM, Grompe M, Duncan AW and Barton MC: P53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology. 57:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
30	Nakamura T, Saito H and Takekawa M: SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nat Commun. 4:17752013. View Article : Google Scholar : PubMed/NCBI
31	Li J, Tan M, Li L, Pamarthy D, Lawrence TS and Sun Y: SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia. 7:312–323. 2005. View Article : Google Scholar : PubMed/NCBI
32	Cao T, Yi S, Yang X and Wu Q: Clinical significance of polo-like kinase 4 as a marker for advanced tumor stage and dismal prognosis in patients with surgical gastric cancer. Technol Cancer Res Treat. 19:15330338209355312020. View Article : Google Scholar : PubMed/NCBI
33	Kahl I, Mense J, Finke C, Boller AL, Lorber C, Győrffy B, Greve B, Götte M and Espinoza-Sánchez NA: The cell cycle-related genes RHAMM, AURKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients. J Cell Biochem. 123:581–600. 2022. View Article : Google Scholar : PubMed/NCBI
34	Zhao JZ, Ye Q, Wang L and Lee SC: Centrosome amplification in cancer and cancer-associated human diseases. Biochim Biophys Acta Rev Cancer. 1876:1885662021. View Article : Google Scholar : PubMed/NCBI